Neuroblastoma Survivors Clinical Trial
Official title:
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
| NCT number | NCT03947346 |
| Other study ID # | 19-160 |
| Secondary ID | |
| Status | Active, not recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | May 9, 2019 |
| Est. completion date | May 2025 |
| Verified date | March 2024 |
| Source | Memorial Sloan Kettering Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
| Status | Active, not recruiting |
| Enrollment | 28 |
| Est. completion date | May 2025 |
| Est. primary completion date | May 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 20 Years |
| Eligibility | Inclusion Criteria: - Diagnosis of neuroblastoma between 0-18 years of age - < 21 years of age at time of study enrollment - Two or more years from completion of systemic chemotherapy and/or radiation therapy Exclusion Criteria: - Patients treated with observation only - Patients with multiple primary cancers |
| Country | Name | City | State |
|---|---|---|---|
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Memorial Sloan Kettering Cancer Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | indicators of renal injury | urine collected from the first morning void will be used to assess urine creatinine | 2 years |